NASDAQ:LTRN

Lantern Pharma Stock Insider Trading

Healthcare > Biotechnology

Buy LTRN

*Your capital is at risk

$3.40

-0.340 (-9.09%)

At Close: Jun 03, 2026

Lantern Pharma Stock Insider Power

Based on the 100 latest insides trades, we have calculated the insider power to be positive at 39.46. In total, the insiders bought 1.04M and sold 750.42K LTRN shares in the last 100 trades. The insider score can be negative despite buy/sell ratio being positive. The score focuses on the quality of the trades.

Insider Power (Last 100 transactions)	39.46
● Buy	1.04M shares
● Sell	750.42K shares
42% Buy Activity Weak Positive Correlation
Buy Signal Medium Confidence May 12, 2026 Analysis Breakdown: Supported by a positive Insider Power Score of 39.46. Confidence increased due to high data reliability score of 100.

Historical Insider Trades

Date	Type	Person	Role	Amount
May 12, 2026 Buy	Common stock purchase warrant (Right to Buy) P-Purchase	Schalop Lee Troy Director	Director	48 544 Value: $110.2K
May 12, 2026 Buy	Common stock purchase warrant (Right to Buy) P-Purchase	Keyser D Jeffrey Director	Director	48 544 Value: $110.2K
May 12, 2026 Buy	Common stock, $0.001 par value P-Purchase	Keyser D Jeffrey Director	Director	48 544 Value: $100.0K
May 12, 2026 Buy	Common stock, $0.001 par value P-Purchase	Schalop Lee Troy Director	Director	48 544 Value: $100.0K
Jan 09, 2026 Buy	Stock Option (Right to Buy) A-Award	Keyser D Jeffrey Director	Director	28 844 Value: $100.7K
Jan 09, 2026 Buy	Stock Option (Right to Buy) A-Award	Keyser D Jeffrey Director	Director	25 000 Value: $87.3K
Jan 09, 2026 Buy	Stock Option (Right to Buy) A-Award	Maccecchini Maria-luisa Director	Director	25 000 Value: $87.3K
Jan 09, 2026 Buy	Stock Option (Right to Buy) A-Award	Maccecchini Maria-luisa Director	Director	21 152 Value: $73.8K
Jan 09, 2026 Buy	Stock Option (Right to Buy) A-Award	Chandru Vijay Director	Director	25 000 Value: $87.3K
Jan 09, 2026 Buy	Stock Option (Right to Buy) A-Award	Chandru Vijay Director	Director	17 307 Value: $60.4K
Jan 09, 2026 Buy	Stock Option (Right to Buy) A-Award	Schalop Lee Troy Director	Director	25 000 Value: $87.3K
Jan 09, 2026 Buy	Stock Option (Right to Buy) A-Award	Schalop Lee Troy Director	Director	18 460 Value: $64.4K
Jan 09, 2026 Buy	Stock Option (Right to Buy) A-Award	Silberstein David S. Director	Director	25 000 Value: $87.3K
Jan 09, 2026 Buy	Stock Option (Right to Buy) A-Award	Silberstein David S. Director	Director	17 307 Value: $60.4K
Dec 18, 2025 Buy	Stock Option (Right to Buy) A-Award	Margrave David R. Chief Financial Officer	C-Suite Officer	20 000 Value: $64.8K
Dec 18, 2025 Buy	Stock Option (Right to Buy) A-Award	Bhatia Kishor G. Chief Scientific Officer	Officer	10 000 Value: $32.4K
Aug 19, 2025 Buy	Stock Option (Right to Buy) A-Award	Schalop Lee Troy Director	Director	5 000 Value: $22.3K
Aug 19, 2025 Buy	Stock Option (Right to Buy) A-Award	Schalop Lee Troy Director	Director	5 000 Value: $22.3K
Jul 24, 2025 Buy	Common Stock J-Other	Schalop Lee Troy	Director	0 Value: $0
Jul 24, 2025 Buy	Common Stock J-Other	Schalop Lee Troy	Director	0 Value: $0
Jun 13, 2025 Sell	Common Stock S-Sale	Kreis Leslie W. 10 Percent Owner	10% Owner	1 903 Value: $6K
Jun 13, 2025 Sell	Common Stock S-Sale	Kreis Leslie W. 10 Percent Owner	10% Owner	4 354 Value: $13.5K
Jun 13, 2025 Sell	Common Stock S-Sale	Kreis Leslie W. 10 Percent Owner	10% Owner	7 206 Value: $22.3K
Jun 13, 2025 Sell	Common Stock S-Sale	Kreis Leslie W. 10 Percent Owner	10% Owner	12 319 Value: $38.1K
Jun 13, 2025 Sell	Common Stock S-Sale	Kreis Leslie W. 10 Percent Owner	10% Owner	14 218 Value: $43.9K

About Insider Power

Insider Power is a proprietary algorithm developed by StockInvest.us to evaluate the significance of insider transactions. The calculation considers the size, type, and timing of transactions, as well as the insider’s role within the company.

It is important to note that, in general, there is little to no correlation between insider transactions and short-term stock price movements. In one of our studies, only 0.22%^* of stocks with insider activity showed a measurable correlation — and even then, it was unclear whether the effect was caused by insider actions or simply by the stock’s broader trend.

While our algorithms are designed to highlight potentially meaningful signals, these cannot be regarded as statistically significant on their own. Insider trading activity should therefore be seen as informative rather than as direct trading guidance. The Insider Power metric was created to present this information in a clearer and more accessible way, helping investors better understand the possible context of insider activity.

* October 6th, 2025 - Tested on 5562 stocks

ABOUT LANTERN PHARMA INC.

Lantern Pharma Inc., a clinical stage biotechnology company, focuses on artificial intelligence, machine learning, and genomic data to streamline the drug development process. Its advanced drug candidate is LP-100, which is in phase II clinical trials to treat metastatic, castration-resistant, and prostate cancer. The company also develops LP-300 as a combination therapy for non or never-smokers with non-small cell lung cancer adenocarcinoma. In ...

Read Full Profile Here